Alnylam Pharmaceuticals (ALNY) EBITDA Margin: History & Chart

Alnylam Pharmaceuticals, Inc.(ALNY)

Biotechnology · Cambridge, MA

$237.10+0.54 (+0.23%)

At close: Aug 28, 2026, 4:00 PM ET

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

2,500 employees

www.alnylam.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yvonne L. Greenstreet

View full financials

ALNY EBITDA Margin Metrics

EBITDA MARGIN

18.98%

EBITDA MARGIN AVG TTM

17.33%

EBITDA MARGIN AVG 3Y

6.22%

EBITDA MARGIN AVG 5Y

-26.14%

EBITDA MARGIN AVG 10Y

-254.07%

EBITDA MARGIN AVG 15Y

-290.68%

EBITDA MARGIN AVG 20Y

-179.92%

CURRENT VS TTM AVG

+9.49%

CURRENT VS 3Y AVG

+204.92%

CURRENT VS 5Y AVG

+172.61%

CURRENT VS 10Y AVG

+107.47%

CURRENT VS 15Y AVG

+106.53%

CURRENT VS 20Y AVG

+110.55%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Alnylam Pharmaceuticals, Inc. (ALNY)	$31.73B	18.98%	17.33%	6.22%	-26.14%
Centene Corp. (CNC)vs ›	$31.99B	-3.26%	-0.27%	1.02%	1.75%
Biogen Inc. (BIIB)vs ›	$32.28B	28.67%	30.68%	30.30%	31.44%
GE HealthCare Technologies Inc. (GEHC)vs ›	$32.40B	16.19%	16.24%	16.31%	17.37%
Zoetis Inc. (ZTS)vs ›	$32.42B	43.14%	42.58%	42.20%	41.87%
Waters Corporation (WAT)vs ›	$31.02B	34.73%	34.58%	34.05%	33.84%
Medline Inc. (MDLN)vs ›	$29.83B	10.26%	11.41%	10.38%	10.38%
DexCom, Inc. (DXCM)vs ›	$34.27B	24.96%	22.62%	21.42%	19.95%
ResMed Inc. (RMD)vs ›	$34.86B	36.98%	37.16%	34.64%	34.36%
Alcon Inc. (ALC)vs ›	$35.12B	24.53%	25.59%	24.02%	22.67%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Alnylam Pharmaceuticals, Inc. (ALNY)

$31.73B

18.98%

17.33%

6.22%

-26.14%

Centene Corp. (CNC)vs ›

$31.99B

-3.26%

-0.27%

1.02%

1.75%

Biogen Inc. (BIIB)vs ›

$32.28B

28.67%

30.68%

30.30%

31.44%

GE HealthCare Technologies Inc. (GEHC)vs ›

$32.40B

16.19%

16.24%

16.31%

17.37%

Zoetis Inc. (ZTS)vs ›

$32.42B

43.14%

42.58%

42.20%

41.87%

Waters Corporation (WAT)vs ›

$31.02B

34.73%

34.58%

34.05%

33.84%

Medline Inc. (MDLN)vs ›

$29.83B

10.26%

11.41%

10.38%

DexCom, Inc. (DXCM)vs ›

$34.27B

24.96%

22.62%

21.42%

19.95%

ResMed Inc. (RMD)vs ›

$34.86B

36.98%

37.16%

34.64%

34.36%

Alcon Inc. (ALC)vs ›

$35.12B

24.53%

25.59%

24.02%

22.67%

EBITDA Margin FAQ

What is the EBITDA margin for Alnylam Pharmaceuticals, Inc. (ALNY)?

The EBITDA margin for ALNY stock is 18.98%.

Is Alnylam Pharmaceuticals, Inc.'s EBITDA margin high or low?

The EBITDA margin of 18.98% is 173% above its 5-year average of -26.14%, near the high end of its 5-year range (-93.62%–30.57%).

What is the TTM average EBITDA margin for Alnylam Pharmaceuticals, Inc. (ALNY)?

The TTM average EBITDA margin for ALNY stock is 17.33%.

What is the 3Y average EBITDA margin for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 3Y average EBITDA margin for ALNY stock is 6.22%.

What is the 5Y average EBITDA margin for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 5Y average EBITDA margin for ALNY stock is -26.14%.

What is the 10Y average EBITDA margin for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 10Y average EBITDA margin for ALNY stock is -254.07%.

What is the 15Y average EBITDA margin for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 15Y average EBITDA margin for ALNY stock is -290.68%.

What is the 20Y average EBITDA margin for Alnylam Pharmaceuticals, Inc. (ALNY)?

The 20Y average EBITDA margin for ALNY stock is -179.92%.

DATE	EBITDA MARGIN
2026-06-30	18.98%
2026-03-31	24.18%
2025-12-31	13.24%
2025-09-30	30.57%
2025-06-30	-0.29%
2025-03-31	5.47%
2024-12-31	-15.34%
2024-09-30	-12.56%
2024-06-30	9.64%
2024-03-31	-6.05%
2023-12-31	-23.41%
2023-09-30	30.27%
2023-06-30	-67.97%
2023-03-31	-42.51%
2022-12-31	-52.03%
2022-09-30	-93.62%
2022-06-30	-80.77%
2022-03-31	-64.37%
2021-12-31	-70.86%
2021-09-30	-90.54%
2021-06-30	-60.92%
2021-03-31	-97.80%
2020-12-31	-112.40%
2020-09-30	-172.13%
2020-06-30	-183.39%
2020-03-31	-203.61%
2019-12-31	-395.24%
2019-09-30	-289.71%
2019-06-30	-501.15%
2019-03-31	-524.70%
2018-12-31	-1047.67%
2018-09-30	-12146.54%
2018-06-30	-635.69%
2018-03-31	-658.60%
2017-12-31	-378.62%
2017-09-30	-714.86%
2017-06-30	-736.93%
2017-03-31	-545.94%
2016-12-31	-644.06%
2016-09-30	-755.81%
2016-06-30	-1015.49%
2016-03-31	-1435.36%
2015-12-31	-1158.03%
2015-09-30	-1155.28%
2015-06-30	-782.07%
2015-03-31	-261.81%
2014-12-31	-176.41%
2014-09-30	-383.54%
2014-06-30	-577.61%
2014-03-31	-3220.11%
2013-12-31	-248.59%
2013-09-30	-327.77%
2013-06-30	-214.12%
2013-03-31	-41.18%
2012-12-31	-1016.19%
2012-09-30	-94.65%
2012-06-30	-45.31%
2012-03-31	-42.61%
2011-12-31	-60.37%
2011-09-30	-53.75%
2011-06-30	-57.39%
2011-03-31	-68.61%
2010-12-31	-52.47%
2010-09-30	-26.97%
2010-06-30	-39.08%
2010-03-31	-41.30%
2009-12-31	-26.04%
2009-09-30	-35.21%
2009-06-30	-83.20%
2009-03-31	-24.66%
2008-12-31	-24.65%
2008-09-30	-6.23%
2008-06-30	-48.19%
2008-03-31	-13.55%
2007-12-31	-10.91%
2007-09-30	-308.24%
2007-06-30	-153.47%
2007-03-31	-315.91%
2006-12-31	-127.55%
2006-09-30	-92.70%
2006-06-30	-168.78%
2006-03-31	-157.57%
2005-12-31	-912.69%
2005-09-30	-702.76%
2005-06-30	-925.27%
2005-03-31	-365.55%
2004-12-31	-180.65%
2004-09-30	-416.83%
2004-06-30	-4977.86%
2004-03-31	-9567.91%
2003-12-31	-46772.73%
2003-09-30	100.00%

DATE

EBITDA MARGIN

2026-06-30

18.98%

2026-03-31

24.18%

2025-12-31

13.24%

2025-09-30

30.57%

2025-06-30

-0.29%

2025-03-31

5.47%

2024-12-31

-15.34%

2024-09-30

-12.56%

2024-06-30

9.64%

2024-03-31

-6.05%

2023-12-31

-23.41%

2023-09-30

30.27%

2023-06-30

-67.97%

2023-03-31

-42.51%

2022-12-31

-52.03%

2022-09-30

-93.62%

2022-06-30

-80.77%

2022-03-31

-64.37%

2021-12-31

-70.86%

2021-09-30

-90.54%

2021-06-30

-60.92%

2021-03-31

-97.80%

2020-12-31

-112.40%

2020-09-30

-172.13%

2020-06-30

-183.39%

2020-03-31

-203.61%

2019-12-31

-395.24%

2019-09-30

-289.71%

2019-06-30

-501.15%

2019-03-31

-524.70%

2018-12-31

-1047.67%

2018-09-30

-12146.54%

2018-06-30

-635.69%

2018-03-31

-658.60%

2017-12-31

-378.62%

2017-09-30

-714.86%

2017-06-30

-736.93%

2017-03-31

-545.94%

2016-12-31

-644.06%

2016-09-30

-755.81%

2016-06-30

-1015.49%

2016-03-31

-1435.36%

2015-12-31

-1158.03%

2015-09-30

-1155.28%

2015-06-30

-782.07%

2015-03-31

-261.81%

2014-12-31

-176.41%

2014-09-30

-383.54%

2014-06-30

-577.61%

2014-03-31

-3220.11%

2013-12-31

-248.59%

2013-09-30

-327.77%

2013-06-30

-214.12%

2013-03-31

-41.18%

2012-12-31

-1016.19%

2012-09-30

-94.65%

2012-06-30

-45.31%

2012-03-31

-42.61%

2011-12-31

-60.37%

2011-09-30

-53.75%

2011-06-30

-57.39%

2011-03-31

-68.61%

2010-12-31

-52.47%

2010-09-30

-26.97%

2010-06-30

-39.08%

2010-03-31

-41.30%

2009-12-31

-26.04%

2009-09-30

-35.21%

2009-06-30

-83.20%

2009-03-31

-24.66%

2008-12-31

-24.65%

2008-09-30

-6.23%

2008-06-30

-48.19%

2008-03-31

-13.55%

2007-12-31

-10.91%

2007-09-30

-308.24%

2007-06-30

-153.47%

2007-03-31

-315.91%

2006-12-31

-127.55%

2006-09-30

-92.70%

2006-06-30

-168.78%

2006-03-31

-157.57%

2005-12-31

-912.69%

2005-09-30

-702.76%

2005-06-30

-925.27%

2005-03-31

-365.55%

2004-12-31

-180.65%

2004-09-30

-416.83%

2004-06-30

-4977.86%

2004-03-31

-9567.91%

2003-12-31

-46772.73%

2003-09-30

100.00%

EBITDA Margin: 18.98%

ALNY EBITDA Margin

ALNY Average EBITDA Margin Chart

ALNY Current vs Average EBITDA Margin Chart

ALNY EBITDA Margin Metrics

ALNY Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

ALNY EBITDA Margin History

Related Metrics